First Detection of Thiamethoxam in a Free-Ranging Insectivorous Bird After its Agricultural Use Ban in Spain.

Neonicotinoids are insecticides used worldwide in phytosanitary and biocidal products and veterinary pharmaceuticals. Recently, some restrictions and bans have been imposed due to their adverse effects on nontarget invertebrates, including pollinators. Although they may have direct and indirect effects on wild vertebrates, few studies have assessed exposure to these compounds in wild birds, so our knowledge remains limited. In the present pilot study we have assessed the prevalence of seven neonicotinoid insecticides and some of their metabolites in whole blood samples from 19 European roller (Coracias garrulus) nestlings and five adult common kestrels (Falco tinnunculus) in an area treated with neonicotinoids to control the palm weevil (Rynchophorus ferrugineus) in southeastern Spain. One European roller nestling born in a palm tree was positive for thiamethoxam, with a concentration of 2.26 ng mL-1, but no residues of neonicotinoids or their metabolites were found in adult common kestrels. Future studies are needed to elucidate potential exposure to neonicotinoids at different times of the year. To our knowledge, this is the first report of the presence of thiamethoxam residues in whole blood of a wild bird species after its ban in Spain. Environ Toxicol Chem 2024;43:1836-1843. © 2024 The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals LLC on behalf of SETAC.

Active monitoring of long-eared owl (Asio otus) nestlings reveals widespread exposure to anticoagulant rodenticides across different agricultural landscapes.

The widespread use of anticoagulant rodenticides (ARs) poses a worldwide threat to farmland wildlife. These compounds accumulate in tissues of both target and non-target species, potentially endangering both direct consumers and their predators. However, investigations on ARs in blood of free-ranging predatory birds are rare. Here, the long-eared owl (Asio otus) has been used as a model predator to assess AR exposure in different agricultural landscapes from a Mediterranean semiarid region. A total of 69 owlets from 38 nests were blood-sampled over 2021 and 2022, aiming to detect AR residues and explore factors that determine their exposure, such as land uses. In addition, prothrombin time (PT) test was conducted to assess potential effects of AR contamination. Overall, nearly all the samples (98.6 %) tested positive for at least one compound and multiple ARs were found in most of the individuals (82.6 %). Among the ARs detected, flocoumafen was the most common compound (88.4 % of the samples). AR total concentration (ΣARs) in blood ranged from 0.06 to 34.18 ng mL-1, detecting the highest levels in the most intensively cultivated area. The analysis of owl pellets from 19 breeding territories showed relevant among-site differences in the contribution of rodents and birds into the diet of long-eared owls, supporting its high dietary plasticity and indicating AR presence at multiple trophic levels. Moreover, a positive and significant correlation was found between ΣARs and PT (Rho = 0.547, p < 0.001), which demonstrates the direct effect of ARs on free-living nestlings. Our results provide a preliminary overview of AR exposure in a little-studied owl species inhabiting agricultural and rural landscapes. Despite the low detected levels, these findings indicate widespread exposure -often to multiple compounds- from early life stages, which raises concern and draws attention to an ongoing and unresolved contamination issue.

Déficit de piruvato cinasa eritrocitaria en España: estudio de 15 casos / Red cell pyruvate kinase deficiency in Spain: A study of 15 cases

Antecedentes y objetivo: El déficit de piruvato cinasa (DPK) es una enfermedad hereditaria rara, que cursa con hemólisis crónica y anemia de intensidad variable. Su heterogeneidad genética es elevada, habiéndose descrito unas 240 mutaciones diferentes. Pacientes y metodología: Se han estudiado 15 pacientes con DPK en los que se ha secuenciado la totalidad del gen PKLR, incluyendo las regiones promotora, exónicas, intrónicas flanqueantes y 3’UTR. Resultados: Según la intensidad del cuadro clínico, los pacientes se han clasificado en 3 grandes grupos: I) grave y muy grave (8 pacientes); II) moderado (2 pacientes), y III) leve (5 pacientes). Se han identificado 18 alelos diferentes, de los que 6 son mutaciones nuevas, no descritas con anterioridad, siendo la mutación PKLRc.721G > T la más prevalente (26,67%), seguida de la mutación PKLR c.1456C > T (13,33%). Trece de los 15 pacientes mostraron un genotipo doble heterocigoto y 2 homocigoto. Conclusiones: En España, la heterogeneidad del patrón genético de la PKLR continúa siendo elevada, aunque algo diferente a la observada en un estudio anterior (1998). Se concluye que la secuenciación total del gen PKLR es imprescindible tanto para la caracterización de los pacientes como para la realización del consejo genético (AU)

Background and objective: Pyruvate kinase deficiency (PKD) is a rare, inherited disease causing chronic hemolysis and anemia of varying intensity. The genetic heterogeneity of PKD is high and, to this day, over 240 different mutations have been identified. Patients and methods: 15 unrelated patients affected by PKD have been studied. PKLR gene sequencing was performed by SANGER, including the determination of promoter regions, exonic, intronic flanking and 3’UTR. Results: Patients were classified into 3 groups based on the intensity of their clinical symptoms: I) severe and very severe (8 patients); II) moderate (2 patients), and III) mild (5 patients). Six out of the 18 alleles found were new mutations which had not been described previously, with the PKLR c.721G>T mutation being the most prevalent (26.67%), followed by the PKLR c.1456C>T mutation (13.33%). Conclusions: In Spain, the genetic heterogeneity of PKLR is still high but differs from that observed in the previous study carried out in 1998. Total PKLR gene sequencing is necessary for the characterization of all patients with PKD and for genetic counseling (AU)